These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1306886)

  • 1. Interleukin-3 and granulocyte-macrophage colony-stimulating factor in combination: clinical implication.
    Frisch J; Ganser A; Hoelzer D; Brugger W; Kanz L; Mertelsmann R; Schulz G
    Med Pediatr Oncol Suppl; 1992; 2():34-7. PubMed ID: 1306886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
    Brugger W; Frisch J; Schulz G; Pressler K; Mertelsmann R; Kanz L
    J Clin Oncol; 1992 Sep; 10(9):1452-9. PubMed ID: 1517788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 3 and interleukin 3/GM-CSF combination therapy--clinical implications.
    Ganser A; Ottmann OG; Hoelzer D
    Stem Cells; 1993 Nov; 11(6):465-73. PubMed ID: 8111306
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
    Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
    J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
    Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
    Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
    Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination protocols of cytokine therapy with interleukin-3 and granulocyte-macrophage colony-stimulating factor in a primate model of radiation-induced marrow aplasia.
    Farese AM; Williams DE; Seiler FR; MacVittie TJ
    Blood; 1993 Nov; 82(10):3012-8. PubMed ID: 8219192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.
    Vadhan-Raj S; Papadopoulos NE; Burgess MA; Linke KA; Patel SR; Hays C; Arcenas A; Plager C; Kudelka AP; Hittelman WN
    J Clin Oncol; 1994 Apr; 12(4):715-24. PubMed ID: 8151315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemopoietic progenitor and myeloid cell kinetics in humans treated with interleukin-3 and granulocyte/macrophage colony-stimulating factor in combination.
    Lord BI; Testa NG; Bretti S; Chang J; Demuynck H; Coutinho L; de Campos E; Fitzsimmons L; Scarffe JH
    Int J Cancer; 1994 Nov; 59(4):483-90. PubMed ID: 7960217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved recovery of myelosuppression following chemotherapy in mice by combined administration of PSK and various cytokines.
    Kohgo Y; Hirayama Y; Sakamaki S; Matsunaga T; Ohi S; Kuga T; Kato J; Niitsu Y
    Acta Haematol; 1994; 92(3):130-5. PubMed ID: 7532894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
    Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
    Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
    J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression.
    Blumenthal RD; Sharkey RM; Goldenberg DM
    J Natl Cancer Inst; 1992 Mar; 84(6):399-407. PubMed ID: 1538418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study.
    Recchia F; De Filippis S; Torchio P; Rea S; Gulino A; Quaglino D; Frati L
    Am J Clin Oncol; 1997 Apr; 20(2):209-14. PubMed ID: 9124202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 3 alone and in combination with GM-CSF in the treatment of patients with neoplastic disease.
    Hoelzer D; Seipelt G; Ganser A
    Semin Hematol; 1991 Apr; 28(2 Suppl 2):17-24. PubMed ID: 2063221
    [No Abstract]   [Full Text] [Related]  

  • 20. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.